keyword
MENU ▼
Read by QxMD icon Read
search

Chronic Heart failure treatment

keyword
https://www.readbyqxmd.com/read/27933206/improving-inflammatory-arthritis-management-through-tighter-monitoring-of-patients-and-the-use-of-innovative-electronic-tools
#1
REVIEW
Piet van Riel, Rieke Alten, Bernard Combe, Diana Abdulganieva, Paola Bousquet, Molly Courtenay, Cinzia Curiale, Antonio Gómez-Centeno, Glenn Haugeberg, Burkhard Leeb, Kari Puolakka, Angelo Ravelli, Bernhard Rintelen, Piercarlo Sarzi-Puttini
Treating to target by monitoring disease activity and adjusting therapy to attain remission or low disease activity has been shown to lead to improved outcomes in chronic rheumatic diseases such as rheumatoid arthritis and spondyloarthritis. Patient-reported outcomes, used in conjunction with clinical measures, add an important perspective of disease activity as perceived by the patient. Several validated PROs are available for inflammatory arthritis, and advances in electronic patient monitoring tools are helping patients with chronic diseases to self-monitor and assess their symptoms and health...
2016: RMD Open
https://www.readbyqxmd.com/read/27931654/the-response-of-the-microcirculation-to-mechanical-support-of-the-heart-in-critical-illness
#2
REVIEW
Sakir Akin, Atila Kara, Corstiaan A den Uil, Can Ince
Critical illness associated with cardiac pump failure results in reduced tissue perfusion in all organs and occurs in various conditions such as sepsis, cardiogenic shock, and heart failure. Mechanical circulatory support (MCS) devices can be used to maintain organ perfusion in patients with cardiogenic shock and decompensated chronic heart failure. However, correction of global hemodynamic parameters by MCS does not always cause a parallel improvement in microcirculatory perfusion and oxygenation of the organ systems, a condition referred to as a loss of hemodynamic coherence between macro- and microcirculation (MC)...
December 2016: Best Practice & Research. Clinical Anaesthesiology
https://www.readbyqxmd.com/read/27931027/anthracycline-induced-cardiotoxicity-in-young-cancer-patients-the-role-of-carnitine
#3
Saro H Armenian
While the increased rates of survival in childhood cancers have increased progressively in recent decades, many childhood cancer survivors will have at least one chronic health condition within 40 years of age. In this regard, cardiovascular complications have emerged as a leading cause of long-term morbidity and mortality in long-term survivors of childhood cancer, likely due to exposure to anthracycline chemotherapy, and outcomes in patients with anthracycline-related cardiomyopathy remain poor. Some progress has been made in understanding the mechanisms at the basis of anthracycline-related cardiomyopathy, which appear to involve generation of reactive oxygen species, leading to mitochondrial dysfunction, followed by myocyte apoptosis and maladaptive left ventricular remodeling...
December 9, 2016: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/27924645/cardiovascular-outcomes-and-tumour-necrosis-factor-antagonists-in-chronic-inflammatory-rheumatic-disease-a-focus-on-rheumatoid-arthritis
#4
Giuliano Tocci, Delia Goletti, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Fabrizio Cantini, Raffaele Scarpa
Many chronic rheumatic diseases have an inflammatory etiology, leading to accelerated atherosclerosis and increased occurrence of vascular diseases. In rheumatoid arthritis (RA), a reduction in cardiovascular (CV) events has been reported under treatments reducing systemic inflammation. Areas covered: Given the central role of tumour necrosis factor alpha (TNFα) in chronic inflammatory conditions and in atherosclerosis, it has been suggested that TNFα-antagonists may reduce CV risk and mortality. Although there are no randomized controlled or head-to-head trials investigating the effect of specific anti-TNF-agents on CV outcomes, observational cohort studies, national registry data, and meta-analyses in RA have reported improved CV outcomes with anti-TNF therapy...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27919821/specific-micrornas-comparisons-in-hypoxia-and-morphine-preconditioning-against-hypoxia-reoxgenation-injury-with-and-without-heart-failure
#5
Hai-Juan Zhu, Zheng-Yi Han, Shu-Fang He, Shi-Yun Jin, Shi-Jin Xu, Xiang-Dong Fang, Ye Zhang
AIMS: Ischemia reperfusion (I/R) injury is an inevitable event arising during the cardiovascular diseases development and the process of potent surgical treatments. microRNAs (miRNAs) are critical regulators of multiple cell processes including I/R injury. The present study aims to quantify miRNA alterations and regulated genes upon hypoxia-reoxygenation (H/R) injury in a rat heart failure model comparing with normal cardiomyocytes. MAIN METHODS: Chronic heart failure was established by injecting doxorubicin (2mg/kg/week) for 6weeks, then H/R was performed on primary cultured cardiomyocytes isolated from normal and failed heart...
December 2, 2016: Life Sciences
https://www.readbyqxmd.com/read/27914612/dexamethasone-induced-diuresis-is-associated-with-inhibition-of-the-renin-angiotensin-aldosterone-system-in-rats
#6
Chao Liu, Ning Ge, Jian-Long Zhai, Jian-Xin Zhang
In heart failure (HF) patients, diuretics remain the cornerstone of therapy to relieve fluid retention. However, the resulting volume loss activates the renin-angiotensin-aldosterone system (RAAS), which blunts the decline in volume depletion and blood pressure. RAAS activation, in turn, compromises the diuretic decongesting effect. Although corticosteroids can induce potent diuresis in HF patients, the effects of corticosteroids on RAAS activation remain unclear. Therefore, we assessed the effects of dexamethasone (Dex) on urine output and plasma angiotensin II and aldosterone levels in rats following water deprivation-induced dehydration, following induction of chronic HF (CHF), and following induction of CHF and volume expansion therapy...
December 2016: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/27914493/patient-factors-associated-with-quality-of-life-in-atrial-fibrillation
#7
Tiffany C Randolph, DaJuanicia N Simon, Laine Thomas, Larry A Allen, Gregg C Fonarow, Bernard J Gersh, Peter R Kowey, James A Reiffel, Gerald V Naccarelli, Paul S Chan, John A Spertus, Eric D Peterson, Jonathan P Piccini
BACKGROUND: As treatment options for atrial fibrillation (AF) increase, more attention is focused on patients' experiences and quality of life (QoL). However, little is known about the factors associated with these outcomes. METHODS: The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) is a disease-specific QoL tool for AF, with domain and summary scores ranging from 0 (the worst QoL) to 100. Using multivariable linear regression, we evaluated factors associated with baseline AFEQT Summary and Subscale Scores in ORBIT AF, a large, community-based AF registry...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27910055/selective-pressure-regulated-retroinfusion-for-gene-therapy-application-in-ischemic-heart-disease
#8
Rabea Hinkel, Christian Kupatt
Coronary heart disease is still the leading cause of death in industrialized nations. Even though revascularization strategies such as coronary artery bypass graft surgery, percutaneous coronary intervention and enhanced drug therapy significantly improved the outcome, about 30 % of patients develop chronic heart failure. Ischemic heart disease and heart failure are characterized by an adverse remodeling of the heart, featuring cardiomyocyte hypertrophy, increased fibrosis and capillary rarefaction. Therefore, gene therapeutic approaches for the treatment of heart failure, such as the modulating contractile function or therapeutic neovascularization, seem to be promising...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27910004/dabigatran-overdose-a-case-report-of-acute-hepatitis-extracorporeal-treatment
#9
Mariagrazia Porru, Antonella Mameli, Maria E Cianchetti, Mario Musu, Paola Schirru, Maria F Ruberto, Doris Barcellona, Francesco Marongiu
Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). The benefits of dabigatran are widely described, but its use in the geriatric population is not without risk. Chronic kidney disease is a common comorbidity with AF, and thus frequent checks of renal function in elderly patients are recommended. We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration...
December 1, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27906998/explaining-the-decline-in-coronary-heart-disease-mortality-in-the-netherlands-between-1997-and-2007
#10
Carla Koopman, Ilonca Vaartjes, Ineke van Dis, W M Monique Verschuren, Peter Engelfriet, Edith M Heintjes, Anneke Blokstra, Dorly J H Deeg, Marjolein Visser, Michiel L Bots, Martin O'Flaherty, Simon Capewell
OBJECTIVE: We set out to determine what proportion of the mortality decline from 1997 to 2007 in coronary heart disease (CHD) in the Netherlands could be attributed to advances in medical treatment and to improvements in population-wide cardiovascular risk factors. METHODS: We used the IMPACT-SEC model. Nationwide information was obtained on changes between 1997 and 2007 in the use of 42 treatments and in cardiovascular risk factor levels in adults, aged 25 or over...
2016: PloS One
https://www.readbyqxmd.com/read/27906521/modeling-the-human-scarred-heart-in-vitro-toward-new-tissue-engineered-models
#11
Janine C Deddens, Amir Hossein Sadeghi, Jesper Hjortnaes, Linda W van Laake, Marc Buijsrogge, Pieter A Doevendans, Ali Khademhosseini, Joost P G Sluijter
Cardiac remodeling is critical for effective tissue healing, however, excessive production and deposition of extracellular matrix components contribute to scarring and failing of the heart. Despite the fact that novel therapies have emerged, there are still no lifelong solutions for this problem. An urgent need exists to improve the understanding of adverse cardiac remodeling in order to develop new therapeutic interventions that will prevent, reverse, or regenerate the fibrotic changes in the failing heart...
December 1, 2016: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/27903565/improving-care-for-heart-failure-patients-in-primary-care-gps-perceptions-a-qualitative-evidence-synthesis
#12
Miek Smeets, Sara Van Roy, Bert Aertgeerts, Mieke Vermandere, Bert Vaes
OBJECTIVES: General practitioners (GPs) play a key role in heart failure (HF) management. Despite multiple guidelines, the management of patients with HF in primary care is suboptimal. Therefore, all the qualitative evidence concerning GPs' perceptions of managing HF in primary care was synthesised to identify barriers and facilitators for optimal care, and ideas for improvement. DESIGN: Qualitative evidence synthesis. METHODS: Searches of MEDLINE, EMBASE, Web of Science and CINAHL databases up to 20/12/2015 were conducted...
November 30, 2016: BMJ Open
https://www.readbyqxmd.com/read/27902477/astragalus-polysaccharide-restores-autophagic-flux-and-improves-cardiomyocyte-function-in-doxorubicin-induced-cardiotoxicity
#13
Yuan Cao, Tao Shen, Xiuqing Huang, Yajun Lin, Beidong Chen, Jing Pang, Guoping Li, Que Wang, Sylvia Zohrabian, Chao Duan, Yang Ruan, Yong Man, Shu Wang, Jian Li
Doxorubicin (adriamycin), an anthracycline antibiotic, is commonly used to treat many types of solid and hematological malignancies. Unfortunately, clinical usage of doxorubicin is limited due to the associated acute and chronic cardiotoxicity. Previous studies demonstrated that Astragalus polysaccharide (APS), the extracts of Astragalus membranaceus, had strong anti-tumor activities and anti-inflammatory effects. However, whether APS could mitigate chemotherapy-induced cardiotoxicity is unclear thus far. We used a doxorubicin-induced neonatal rat cardiomyocyte injury model and a mouse heart failure model to explore the function of APS...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27894487/2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure
#14
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer
No abstract text is available yet for this article.
December 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27894486/comments-on-the-2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure
#15
A Sionis, Alessandro Sionis Green, Nicolas Manito Lorite, Héctor Bueno, Antonio Coca Payeras, Beatriz Díaz Molina, José Ramón González Juanatey, Luis Miguel Ruilope Urioste, José Luis Zamorano Gómez, Luis Almenar Bonet, Albert Ariza Solé, Ramón Bover Freire, José Luis Lambert Rodríguez, Esteban López de Sá, Silvia López Fernández, Roberto Martín Asenjo, Sonia Mirabet Pérez, Domingo Pascual Figal, Javier Segovia Cubero, Alfonso Varela Román, José Alberto San Román Calvar, Fernando Alfonso Manterola, Fernando Arribas Ynsaurriaga, Arturo Evangelista Masip, Ignacio Ferreira González, Manuel Jiménez Navarro, Francisco Marin Ortuño, Leopoldo Pérez de Isla, Luis Rodríguez Padial, Pedro Luis Sánchez Fernández, Alessandro Sionis Green, Rafael Vázquez García
No abstract text is available yet for this article.
December 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27891294/prevalence-and-clinical-impact-of-cachexia-in-chronic-illness-in-europe-usa-and-japan-facts-and-numbers-update-2016
#16
EDITORIAL
Stephan von Haehling, Markus S Anker, Stefan D Anker
Cachexia is a serious clinical consequence of almost all chronic diseases when reaching advanced stages. Its prevalence ranges from 5-15% in end-stage chronic heart failure to 50-80% in advanced malignant cancer. Cachexia is also frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD) or neurological diseases, and rheumatoid arthritis. Mortality rates of patients with cachexia range from 15-25% per year in severe COPD through 20-40% per year in patients with chronic heart failure or chronic kidney disease to 20-80% in cancer cachexia...
December 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27891061/noninvasive-positive-pressure-ventilation-in-chronic-heart-failure
#17
REVIEW
Hao Jiang, Yi Han, Chenqi Xu, Jun Pu, Ben He
Instruction and Objectives. Noninvasive positive pressure ventilation (NPPV) alleviates sleep-disordered breathing (SDB) and it may improve cardiac function in SDB patients. Because large randomized controlled trials directly evaluating the impact of NPPV on cardiac function are lacking, we conducted a meta-analysis of published data on effectiveness of NPPV in improving cardiac function in patients with chronic heart failure regardless of SDB presence. Methods. Controlled trials were identified in PubMed, OVID, and EMBASE databases...
2016: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://www.readbyqxmd.com/read/27890915/pharmacological-evidence-a-new-therapeutic-approach-to-the-treatment-of-chronic-heart-failure-through-sur2b-kir6-1-channel-in-endothelial-cells
#18
Shang Wang, Chao-Liang Long, Jun Chen, Wen-Yu Cui, Yan-Fang Zhang, Hao Zhang, Hai Wang
Both iptakalim (Ipt) and natakalim (Nat) activate the SUR2B/Kir6.1 channel, an ATP-sensitive potassium channel (KATP) subtype, with high selectivity. In this study we investigated the therapeutic effects of Ipt and Nat against isoproterenol-induced chronic heart failure (ISO-CHF) in rats, and demonstrated a new therapeutic approach to the treatment of CHF through activation of the SUR2B/Kir6.1 channel in endothelial cells. In ISO-CHF rats, oral administration of Nat (1, 3, 9 mg·kg(-1)·d(-1)) or Ipt (3 mg·kg(-1)·d(-1)) for 60 days significantly improved cardiac dysfunction, reversed cardiac remodeling, significantly attenuated the pathological increases in BNP levels, and improved endothelial dysfunction by adjusting the balance between endothelin and NO systems...
November 28, 2016: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/27889372/-non-invasive-ventilation-in-children-do-we-need-more-evidence
#19
G Mortamet, G Emeriaud, P Jouvet, B Fauroux, S Essouri
Respiratory failure is the leading cause of hospital admissions in the pediatric intensive care unit (PICU) and is associated with significant morbidity and mortality. Mechanical ventilation, preferentially delivered by a non-invasive route (NIV), is currently the first-line treatment for respiratory failure since it is associated with a reduction in the intubation rate. This ventilatory support is increasingly used in the PICU, but its wider use contrasts with the paucity of studies in this field. This review aims to describe the main indications of NIV in acute settings: (i) bronchiolitis; (ii) postextubation respiratory failure; (iii) acute respiratory distress syndrome; (iv) pneumonia; (v) status asthmaticus; (vi) acute chest syndrome; (vii) left heart failure; (viii) exacerbation of chronic respiratory failure; (ix) upper airway obstruction and (x) end-of-life care...
November 23, 2016: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/27886920/why-we-have-to-use-cardiac-resynchronization-therapy-pacemaker-more
#20
REVIEW
Jean-Claude Daubert, Raphaël Martins, Christophe Leclercq
Both cardiac resynchronization therapy with a pacemaker (CRT-P) and with a biventricular implantable cardioverter-defibrillator (CRT-D) are electrical treatment modalities validated for the management of chronic heart failure. There is no strong scientific evidence that a CRT-D must be offered to all candidates. Common sense should limit the prescription of these costly and complicated devices. The choice of CRT-P is currently acceptable. A direction to explore could be to downgrade from CRT-D to CRT-P at the time of battery depletion in patients with large reverse remodeling and no ventricular tachycardia and ventricular fibrillation detected...
January 2017: Heart Failure Clinics
keyword
keyword
114544
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"